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ABSTRACT
Introduction Owing to their propensity for being
associated with infections, biofilms have become a
focus in infectious disease research. There is evidence
suggesting that statins, which are commonly used for
prevention of cardiovascular disease, may prevent biofilmassociated infections, but this association has not been
well-understood.
Methods and analysis This systematic review protocol
will include six database searches from their inception
to 20 August 2020. A medical librarian will conduct the
searches in PubMed, EMBASE, Web of Science, CINAHL,
LILACS and CENTRAL, without any limits. Bibliographies of
selected articles, previously published reviews and highyield journals that publish on statins and/or biofilms will
be searched to identify additional articles. The screening
and data extraction will be conducted by two independent
reviewers using DistillerSR. All included papers will also
be evaluated for quality using Cochrane Risk of Bias
Assessment tool, and we will examine for publication bias.
If there are two or more studies with quantitative estimates
that can be combined, we will conduct a meta-analysis
after assessing for heterogeneity. We will report all findings
according to the Preferred Reporting Items for Systematic
reviews and Analyses-P framework.
Ethics and dissemination There are conflicting results
on the effect of statins on biofilm-associated infections.
The rise of antibiotic resistance in medical settings
warrants a deeper understanding of this association,
especially if statins can be used as a novel antibiotic. The
findings of this review will assess the association between
statin use and biofilm-associated infection to inform future
medical practice. No formal ethical review is required
for this protocol. All findings will be published in a peerreviewed journal.
PROSPERO registration number CRD42020193985.

BACKGROUND
Biofilms are an ‘assemblage of surfaceassociated microbial cells enclosed in an
extracellular polymeric substance matrix’.1
Although they are sometimes beneficial to
cellular processes in both plants and animals,
biofilms also promote chronic infection by
Staphylococcus aureus and other bacteria.2
Developing frequently at the intersection
between surface and aqueous media, they
also pose significant risks for patients with
implanted medical devices.1 In addition, a

Strengths and limitations of this study
Ź This review will access >3 databases, multiple other

sites, and will have no language limits.
Ź We will be assessing the quality of studies.
Ź If data are available, we will conduct meta-analysis.
Ź There is potential for heterogeneity in included

articles.
Ź Reproducibility of the study based on ability to

pay for access to the databases like EMBASE and
Web of Science, and shift in the PubMed platform
from Legacy PubMed to the New PubMed might be
limited.

growing number of studies demonstrate that
biofilms are a significant source of antibioticresistance, particularly in nosocomial
settings.1 2 With a shrinking number of tools
available to address common bacterial infections, they have therefore become a major
focus of research on infectious disease.3 4
Statins are commonly used for primary
prevention of cardiovascular disease.5–8
As a class, they have high safety and tolerability with few side effects when used for
lowering lipids in patients with elevated
cholesterol.5 Although all statins act by
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase to reduce cholesterol
synthesis, they can be lipophilic or hydrophilic depending on their tissue selectivity.2 6
Studies suggest that while both classes have
similar lipid-lowering outcomes, they vary in
their anti-inflammatory, anticancer and antimicrobial effects.5 Simvastatin, for instance,
has been shown to have activity against
clinical isolates and biofilms of methicillinsensitive S. aureus and methicillin-resistant
S. aureus—suggesting it might have a role in
treatment of S. aureus infections.5 Atorvastatin, another lipophilic statin has also been
shown to abrogate biofilm formation in periodontal disease.7 8 Fewer antimicrobial and
antibiofilm effects have been documented in
hydrophilic statins.9 10 Whether either class of
drug is efficacious eradicating or preventing
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biofilms remains controversial; however, as research
shows mixed results for statin treatment of biofilmforming bacterial infections.10
The mechanisms by which statins inhibit bacterial
growth is unclear. There is some evidence that they modulate toll-like receptors, host sentinels of innate and adaptive immunity and operate through anti-inflammatory
pathways shown to reduce the formation of biofilms.11 12
Another possible mechanism is statin effects on metalloproteases (matrix metalloproteases (MMPs)) shown to
prolong inflammatory response and fuel biofilm formation.13 Studies have shown that specific statins inhibit the
expression of MMP-1, MMP-2, MMP-8 and MMP-9 both
in vivo and in vitro.14 15 Finally, the cholesterol-lowering
effects of statins may extend to bacterial pathogens as
cholesterol is a critical component of bacteria membrane
integrity.16 Some biofilm-producing organisms like Salmonella also bind and form biofilms on cholesterol particles.
Therefore, reducing levels of circulating lipids may limit
the potential for biofilm formation.17
Research on the control and prevention of biofilms
is currently being pursued in variety of fields including
wound treatment, periodontal infections, vaginal conditions like bacterial vaginosis and vaginal candidiasis,
nosocomial infections, medical device implantation and
antimicrobial resistance.18 Statins may offer new hope
for the treatment and the prevention of one of bacteria’s
most recalcitrant features—but there currently remains
controversy around their usefulness. As a consequence,
there is a compelling need for systematic review of the
literature and determination of whether a meta-analysis
of statin effects on biofilm is warranted. Consequently,
this review will examine the literature on statins and their
effects on biofilm formation and prevention.

METHODS
This systematic review and meta-analysis will be conducted
according to the Cochrane Handbook for Systematic
Reviews of Interventions (V.6.1) and the findings will be
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines.19 20
Patient and public involvement
Patients and the public were not involved in setting the
research question or the outcome measures.
Purpose of the protocol
To conduct a detailed synthesis of the literature examining the effects of statins on biofilm-associated infections.
Eligibility criteria
Types of studies to be included
Observational and experimental study designs will be
included (cohort, case–control, cross-sectional and clinical studies). We will not include case reports. There will
be no limitations with regards to the number of participants in the studies.
2

Participants/population
Participants may be of any age, with and without evidence
of an infection associated with biofilm formation.
1. Inclusion: Individuals who were treated with any statins
and had a biofilm-associated infection.
2. Exclusion: Animal studies, lab studies and in vitro
studies.
Intervention(s), exposure(s)
Studies comparing any antibiotic regimen plus statins
(intervention group) as compared with the same antibiotic regimen without statins (control group). Studies in
which statins were offered by any route of administration
(orally or intravenously), and with any dose, provided the
same route and the same dose were used in both experimental and control groups.
Comparator(s)/control
We will include studies with a placebo replacing the statin,
as well as studies of antibiotic regimens alone (without
placebo).
Types of outcome measures
Successful reduction of the infection associated with
biofilm formation shown from measures of effect such as
standard mean difference and HR.
Eligibility criteria
Inclusion criteria
1. Research findings published in peer-reviewed journals.
2. The iterature published since September 1987.
Exclusion criteria
1. Animal studies.
2. Dissertation/theses.
3. Studies without reported estimates.
4. Laboratory in vitro studies.
Information sources and search strategy
Primary search databases
As the first statin was approved for use in September
1987, only paper published between that date and August
2020, will be included. However, no other restrictions
on language or status of publication when searching the
electronic databases or other resources will be included.
A literature search will be conducted to identify all
published and unpublished studies. The following electronic databases will be searched for identifying potential
studies: MEDLINE, EMBASE, Cochrane Central Register
for Clinical Trials, Web of Science, CINAHL and LILACS.
We will include all articles published in these databases
beginning in September 1987. Search strategies will be
translated for each database. We will include controlled
vocabulary (eg, MeSH and Emtree) and keyword search
terms to identify studies. An example of the search strategy
for PubMed is listed below. The full set of search terms for
each database will be included at the time of publication
of the systematic review. We will scan the reference lists of
eligible studies and relevant review articles to identify any
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potentially eligible studies to be included into the review.
The searches will be conducted by a medical librarian
(DJMC) who has the necessary training and skills in
conducting database searches. There will be no language
limits, and translations will be requested for articles
published in languages other than English.
Secondary hand-search of databases
We will also include the following databases, including
pharmaceutical company databases, to be searched for
additional studies on the association between statins and
biofilm:
1. Health Management Information Consortium
database.
2. National Technical Information Service database.
3. OpenGrey.
4. AstraZeneca Clinical Trials.
5. Bristol-Myers Squibb Clinical Trial Registry.
6. Merck Clinical Trial Registry.
7. Pfizer Clinical Trial Registry.
8. ClinicalTrials.gov.
9. Current Controlled Trials metaRegister of Controlled
Trials.
10. Eli Lilly and Company Clinical Trial Registry.
11. EU Clinical Trials Register.
12. International Clinical Trials Registry Platform Search
Portal.
13. International
Federation
of
Pharmaceutical
Manufacturers and Associations (IFPMA) Clinical
Trials Portal.
14. Roche Clinical Trials Results Database.
Within the above databases, studies will be selected
depending on their use of statins for infection-related
treatments.
We will conduct manual searches of the table of
contents for the following journals published between
September1987 and up to August 2020:
1. New England Journal of Medicine.
2. Antimicrobial Agents and Chemotherapy.
3. Cell, Host and Microbe.
4. Medical Mycology.
5. JAMA Cardiology.
6. Medical Mycology.
7. JAMA Internal Medicine.
Search terms for PubMed
Infection OR “infections” [MeSH]
AND
biofilm OR biofilms OR bacterial adhesions OR bacterial adhesin OR biofouling OR plaque OR Microcosm OR
microcosms OR multi-species OR defined-multispecies
OR multispecies OR microbial consortia OR microbial
consortium OR “biofilms” [mesh] OR “bacterial adhesion” [mesh] OR “Adhesins, Bacterial” [Mesh] OR “dental
plaque” [mesh] OR “Microbial Consortia” [Mesh]
AND
statin OR statins OR hydroxymethylglutaryl-coa
reductase inhibitors OR HMG-CoA OR HMGCoA OR
Valencia DY, et al. BMJ Open 2021;11:e046290. doi:10.1136/bmjopen-2020-046290

“Hydroxymethylglutaryl-Coenzyme A” OR atorvastatin
OR Lipitor OR Torvast OR Fluvastatin OR Lescol OR
Pravachol OR Lipostat OR Selektine OR Rosuvastatin OR
Crestor OR Simvastatin OR Zocor OR Lipex OR Pravastatin OR Lovastatin OR Mevacor OR Altocor OR Altoprev
OR Pitavastatin OR Livalo OR Pitava OR cerivastatin OR
“hydroxymethylglutaryl-coa reductase inhibitors”[MeSH]
OR “Lovastatin” [Mesh] OR “Pravastatin” [Mesh] OR
“Simvastatin” [Mesh].
Study records
Screening of articles to be selected into the review
Titles and abstracts will be identified and retrieved from
the included databases using the search strategy. Handsearches or high-yield journals, grey literature and pharmaceutical company databases will also be conducted to
identify additional papers pertaining to statins and their
use to prevent or treat infection. Hand-searches will also
be conducted according to our inclusion and exclusion
criteria. Once all database and hand-searches have been
completed, references will be deduplicated in EndNote
and exported to DistillerSR for review. This will be done by
an experienced librarian familiar with database searches.
DistillerSR is a systematic review software that streamlines screening and data extraction for reviewers. Within
this software, the review team will be assigned to specific
tasks in the screening, full-text review and data extraction
processes. Each title and abstract will be screened independently by two review authors to identify studies
that will be included in the review based on previously
stated inclusion criteria. Studies that meet the criteria
for inclusion after title and abstract review will undergo
full-text review by two study authors. Discrepancies will
be resolved by a third member of the review team. Data
will be extracted from studies that are included after fulltext review using standardised extraction forms that are
automated, but also customisable, in DistillerSR. Data
extracted within DistillerSR will be exported for further
analysis.
Data
Data management and extraction
A standardised form created in DistillerSR will be used
to extract data from the included studies. The data we
will collect from each study include study setting, study
population, participant demographics, description of the
intervention including statin(s) used, dosage, route of
administration and duration. We will also describe primary
and secondary outcomes, frequency of outcome measurements, attrition rates, longitudinal studies outcomes and
times of measurement. At all of these stages, if there is any
discordance between two review authors, we will have a
third author serve as a tiebreaker.
If statistical measures of effect are presented in two or
more papers, we will conduct subgroup analyses for the
kinds of infections, populations, study design, age (paediatric vs adult) groups and types of statins. Sensitivity
3
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analysis will be performed by study design (experimental
and observational studies) and by quality of the studies.
Risk of bias and quality assessment
We will use the Cochrane Bias Assessment Tool to determine the risk of bias in the studies.21 This will be assessed
independently by two reviewers. We will use the NewcastleOttawa Quality Assessment Scale to assess the risk of bias
of cohort and case–control studies.22
Data synthesis
If there are measures that can be synthesised appropriately, we will summarise our findings using quantitative
methods. However, if quantitative synthesis is inappropriate, we will describe the study findings using narrative
analysis. A spreadsheet will be created to abstract data on
all variables, and to determine concordant and discordant conclusions about articles included in the review.
Data will be summarised in tables. We will extract both
the unadjusted and adjusted measures of effect from the
selected studies.
If there are statistical measures of effect presented in
two or more papers, we will assess the heterogeneity of
the studies. A meta-analysis will be conducted if heterogeneity is not a major concern. Heterogeneity will be determined using the χ2 and I2 tests. We will pool data with a
random effects model when there are sufficient studies
to summarise. If heterogeneity is identified (I2 >40%)
and there are sufficient number of studies included in
the review, we will examine for reasons for heterogeneity.
Subgroup analyses and sensitivity analyses will be considered if they are necessary.
We will assess for publication bias by use of funnel plots
when the number of studies reported is >9 studies. All
analyses will be conducted using STATA statistical software. All tests will be two-tailed, and p<0.05 will be considered statistically significant.
We will use the Grading of Recommendations Assessment, Development and Evaluation methodology to rate
the certainty of evidence as high, moderate, low or very
low.23 Register of Controlled Trials begin as high certainty
evidence but can be rated down because of risk of bias,
imprecision, inconsistency, indirectness and publication
bias. If the limitation of the evidence is considered serious,
the evidence is downgraded by one level; if the limitation
of the evidence is considered serious, the evidence is
downgraded by two levels. Observational studies begin as
low-quality evidence but can be rated upwards for a large
magnitude of effect, a dose–response gradient or the
presence of plausible confounders or other biases that
increase confidence in the estimated effect.

ETHICS AND DISSEMINATION
There are conflicting results on the effect of statins on
biofilm-associated infections. The rise of antibiotic resistance in medical settings warrants a deeper understanding
of this association, especially if statins can be used as a
4

novel antibiotic. The findings of this review will assess
the association between statin use and biofilm-associated
infection to inform future medical practice. No formal
ethical review is required for this protocol. All findings
will be published in a peer-reviewed journal.
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